FDA clears Regeneron's Livsayis, first siRNA treatment for gMG
Regeneron's siRNA drug Livsayis won FDA approval for AChR antibody-positive gMG, delivering a 2.3-point placebo-adjusted MG-ADL gain at 24 weeks with four doses a year.
TAG C-7292 · 612 words on the filing

Summary of findings
- Livsayis (cemdisiran) approved by FDA for adults with AChR antibody-positive gMG, dosed four times a year
- NIMBLE trial: 190 subjects, 2.3-point placebo-adjusted MG-ADL total score improvement at 24 weeks
- Approved C5 inhibitors have delivered placebo-adjusted MG-ADL differences of 1.6 to 2.1 points
- GlobalData analysts predict $1.9 billion peak sales; US price and launch date not yet disclosed
- Regeneron licenses Livsayis from Alnylam under a $1 billion alliance agreed in 2019
Regeneron's Livsayis (cemdisiran) has won FDA approval for adults with AChR antibody-positive generalised myasthenia gravis, adding a therapy dosed only four times a year to a crowded US market. It is the first siRNA-based treatment for gMG and the first Regeneron approval in neurology.
The drug switches off production of complement C5, a target with a long record in this disease. AstraZeneca's Alexion unit said earlier this week that Klygefa (gefurulimab) had cleared FDA review, the fifth C5 inhibitor indicated for gMG in the US. Livsayis works on the same complement and will also compete with three drugs targeting FcRn.
In the 190-subject NIMBLE trial, a quarterly subcutaneous injection of Livsayis achieved a statistically significant 2.3-point placebo-adjusted improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at 24 weeks in symptomatic patients with anti-AChR antibodies. Separation from placebo occurred within two weeks of the first dose.
Regeneron's summary of NIMBLE also reports a 2.2-point improvement on placebo. Those two figures do not reconcile with a 2.3-point placebo-adjusted gain, and the release discloses no P-value, no detailed safety data and no active comparator. That leaves the headline result harder to weigh than the "statistically significant" label implies.
Historical data from approved C5 inhibitors show placebo-adjusted treatment differences in MG-ADL total scores of 1.6 to 2.1 points, which places Livsayis at the upper end of the class on the reported measure. Whether that advantage survives contact with real-world patients depends on the unanswered questions above.
Lead investigator Tuan Vu of the University of South Florida Morsani College of Medicine framed the approval around what approved medicines leave behind. Despite the growing number of options, he said, many patients still experience "suboptimal disease control, whether from waning of therapeutic effect, inadequate response, or high treatment burden." In NIMBLE, Livsayis delivered "rapid, deep disease control, maintained through the end of dosing intervals," and he called the regimen "a compelling treatment option."
Real-world figures support the concern. Roughly 20% to 50% of patients experience an insufficient response to a first gMG treatment, and some benefit from switching between medicines and drug classes. The dosing interval is the commercial pitch here: four injections a year in a market where switching between products is routine.
Price and launch date remain undisclosed. GlobalData analysts predict peak sales of $1.9 billion, contingent on pricing at levels similar to current drugs — a forecast that assumes both reimbursement and prescriber switching.
Part of that forecast depends on combination use with Regeneron's anti-C5 antibody Veopoz (pozelimab). Veopoz is FDA-approved for CHAPLE disease but disappointed in a gMG trial, and Regeneron now runs late-stage trials of the combination in paroxysmal nocturnal haemoglobinuria and geographic atrophy. That combination pipeline, not the monotherapy, carries much of the modelling.
Regeneron licenses Livsayis from Alnylam under a $1 billion alliance agreed in 2019. As Regeneron's first approved siRNA therapy, the clearance "marks a meaningful step forward for our neuroscience pipeline as we relentlessly pursue bold, new approaches to transform care for people living with serious neurological diseases," chief scientific officer George Yancopolous said.
What the announcement does not settle is the commercial question. Price, launch date, payer positioning and the full safety profile remain unpublished, and the trial figures as reported do not produce a clean placebo-adjusted delta. On paper, a quarterly RNA therapy is a real addition to a disease where treatment burden is a documented failure point. Whether it becomes a $1.9 billion product depends on details Regeneron has not yet put out.
via FDA industry wire (Google News) (Source)
More from Rebecca Stone
Show full bio
Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
18 articles
Linked filings
- V-8328
- K-7275
- E-2578
- K-8685
- K-2547